Nurse-Led PrEP program boosts HIV prevention in Women's clinics

NCT ID NCT05095818

Completed Prevention Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether a registered nurse could help women at risk for HIV learn about and start PrEP (a daily pill that prevents HIV) during OB/GYN visits. 440 women were randomly assigned to either standard care or a nurse-led program that included counseling and lab tests. The goal was to see if the nurse-led approach increased awareness and use of PrEP.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Emtricitabine 200 mg/Tenofovir disoproxil fumarate 300 mg (PrEP)
What this could lead to: If successful, this approach could make it easier for women to access HIV prevention medication during routine OB/GYN visits.
What could go wrong: This is a completed feasibility study, not a large-scale trial. The results may not apply to all clinics or populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRE-EXPOSURE PROPHYLAXIS (PREP) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRE-EXPOSURE PROPHYLAXIS (PREP)

Contacts and locations

Locations

Johns Hopkins Outpatient Center

Baltimore, Maryland, 21287, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.